Biotech News

News Releases

ACADIA Pharmaceuticals Inc. (ACAD)ACADIA Pharmaceuticals Inc.2024-10-16 20:07 ESTFDA / regulatory

October 16, 2024

General

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

April 22, 2024

General

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Open original release

Related news

ACADACADIA Pharmaceuticals Inc.2026-07-06 13:04 EST

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

ACADACADIA Pharmaceuticals Inc.2026-06-26 10:49 EST

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

ACADACADIA Pharmaceuticals Inc.2026-05-06 20:05 EST

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACADACADIA Pharmaceuticals Inc.2026-04-30 20:05 EST

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

ACADACADIA Pharmaceuticals Inc.2026-04-28 12:00 EST

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

USNAUsana Health Sciences, Inc.2026-07-14 20:15 EST

USANA Schedules Second Quarter 2026 Earnings Release and Conference Call

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

XOMAXOMA Corporation2026-07-14 13:00 EST

XOMA Royalty Announces Closing of Its Acquisition by Ligand

ARTLArtelo Biosciences2026-07-14 12:47 EST

Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026

ICCMIceCure Medical2026-07-14 12:32 EST

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

View all latest news

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ACADZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

ACADZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

ACADBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

ACADGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

ACADMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 25.50 USD
Market cap: 4.49B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States